Antipsychotic treatment of adults in the United States

Journal of Clinical Psychiatry

Volumn 76, Issue 10, 2015, Pages 1346-1353

  Olfson, Mark ^a   King, Marissa ^b   Schoenbaum, Michael ^c  

^a New York Presbyterian Columbia University Medical Center   (United States)

^b YALE SCHOOL OF MANAGEMENT   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; AUTISM; BIPOLAR DISORDER; CONTROLLED STUDY; DEMENTIA; DEPRESSION; DRUG USE; FEMALE; GROUPS BY AGE; HUMAN; ICD-9; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; MIDDLE AGED; OBSERVATIONAL STUDY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; PSYCHIATRIST; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SEX; UNITED STATES; VERY ELDERLY; YOUNG ADULT; AGE; CLINICAL PRACTICE; EPIDEMIOLOGY; PSYCHOTIC DISORDERS; SEX DIFFERENCE; STATISTICS AND NUMERICAL DATA;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SEX FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84945397890     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.15m09863     Document Type: Article

References (44)

1. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011. IMS Health Web site. http://www. imshealth.com/ims/Global/Content/Insights/ IMS Institute for Healthcare Informatics/IHII- Medicines-in-U.ŞReport-2011.pdf. Updated April 2012. Accessed August 8, 2015.
2. Leucht S, Heres S, Kissling W, et al. Evidencebased pharmacotherapy of schizophrenia. Int J Neuropsychopharmacol. 2011;14(2):269-284.
3. Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs. 2010;24(7):575-593.
4. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs. 2011;25(2):109-127.
5. Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177-184.
6. Leslie DL, Rosenheck R. Off-label use of antipsychotic medications in Medicaid. Am J Manag Care. 2012;18(3):e109-e117.
7. Schulze J, Glaeske G, van den Bussche H, et al. Prescribing of antipsychotic drugs in patients with dementia: a comparison with agematched and sex-matched non-demented controls. Pharmacoepidemiol Drug Saf. 2013;22(12):1308-1316.
8. Kleijer BC, van Marum RJ, Egberts AC, et al. Risk of cerebrovascular events in elderly users of antipsychotics. J Psychopharmacol. 2009;23(8):909-914.
9. Rigler SK, Shireman TI, Cook-Wiens GJ, et al. Fracture risk in nursing home residents initiating antipsychotic medications. J Am Geriatr Soc. 2013;61(5):715-722.
10. Hwang YJ, Dixon SN, Reiss JP, et al. Atypical antipsychotic drugs and the risk for acute kidney injury and other adverse outcomes in older adults: a population-based cohort study. Ann Intern Med. 2014;161(4):242-248.
11. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294(15):1934-1943.
12. Kales HC, Zivin K, Kim HM, et al. Trends in antipsychotic use in dementia 1999-2007. Arch Gen Psychiatry. 2011;68(2):190-197.
13. Pathak P, West D, Martin BC, et al. Evidencebased use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv. 2010;61(2):123-129.
14. Simoni-Wastila L, Ryder PT, Qian J, et al. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry. 2009;17(5):417-427.
15. Yang M, Barner JC, Lawson KA, et al. Antipsychotic medication utilization trends among Texas veterans: 1997-2002. Ann Pharmacother. 2008;42(9):1229-1238.
16. Crystal S, Olfson M, Huang C, et al. Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff. 2009;28(5):w770-w781.
17. Gellad WF, Aspinall SL, Handler SM, et al. Use of antipsychotics among older residents in VA nursing homes. Med Care. 2012;50(11):954-960.
18. MEPS-HC panel design and data collection process. Agency for Healthcare Research and Quality Web site. http://meps.ahrq.gov/survey- comp/hc-data-collection.jsp. Accessed August 8, 2015.
19. Mirandola M, Andretta M, Corbari L, et al. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf. 2006;15(6):412-420.
20. Alessi-Severini S, Biscontri RG, Collins DM, et al. Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006. Psychiatr Serv. 2008;59(5):547-553.
21. Kaye JA, Bradbury BD, Jick H. Changes in antipsychotic drug prescribing by general practitioners in the United Kingdom from 1991 to 2000: a population-based observational study. Br J Clin Pharmacol. 2003;56(5):569-575.
22. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2):125-132.
23. Byers AL, Yaffe K, Covinsky KE, et al. High occurrence of mood and anxiety disorders among older adults: the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2010;67(5):489-496.
24. Young RC, Kiosses D, Heo M, et al. Age and ratings of manic psychopathology. Bipolar Disord. 2007;9(3):301-304.
25. Oostervink F, Boomsma MM, Nolen WA; EMBLEM Advisory Board. Bipolar disorder in the elderly; different effects of age and of age of onset. J Affect Disord. 2009;116(3):176-183.
26. Al Jurdi RK, Nguyen QX, Petersen NJ, et al. Acute bipolar I affective episode presentation across life span. J Geriatr Psychiatry Neurol. 2012;25(1):6-14.
27. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106.
28. Weissman MM, Bland RC, Canino GJ, et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA. 1996;276(4):293-299.
29. Leclerc E, Mansur RB, Brietzke E. Determinants of adherence to treatment in bipolar disorder: a comprehensive review. J Affect Disord. 2013;149(1-3):247-252.
30. Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology. 1999;52(1):78-84.
31. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2010;36(1):71-93.
32. Vieta E, Valentí M. Pharmacological management of bipolar depression: acute treatment, maintenance, and prophylaxis. CNS Drugs. 2013;27(7):515-529.
33. Wright BM, Eiland EH 3rd, Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature. Pharmacotherapy. 2013;33(3):344-359.
34. Gareri P, De Fazio P, Manfredi VG, et al. Use and safety of antipsychotics in behavioral disorders in elderly people with dementia. J Clin Psychopharmacol. 2014;34(1):109-123.
35. Ballard C, Hanney ML, Theodoulou M, et al; DART-AD investigators. The dementia antipsychotic withdrawal trial (DART-AD): longterm follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151-157.
36. Wang PS, Lane M, Olfson M, et al. Twelve-month use of mental health services in the United States: results from the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):629-640.
37. Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350(7):h369.
38. US Food and Drug Administration. Public health advisory: deaths with antipsychotics in elderly patients with behavioral disturbances. http:// www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ucm053171.htm. Published April 11, 2005. Accessed August 26, 2015.
39. US Food and Drug Administration. FDA requests boxed warnings on older class of antipsychotic drugs. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/2008/ ucm116912.htm. Published June 16, 2008. Accessed August 26, 2015.
40. Dorsey ER, Rabbani A, Gallagher SA, et al. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96-103.
41. United States Government Accountability Office. Antipsychotic drug use: HHS has initiatives to reduce use among older adults in nursing homes, but should expand efforts to other settings. http://www.gao.gov/ assets/670/668221.pdf. Updated January 2015. Accessed August 8, 2015.
42. Abrams RC, Young RC. Crisis in access to care: geriatric psychiatry services unobtainable at any price. Public Health Rep. 2006;121(6):646-649.
43. Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756-761.
44. Callahan CM, Boustani MA, Unverzagt FW, et al. Effectiveness of collaborative care for older adults with Alzheimer disease in primary care: a randomized controlled trial. JAMA. 2006;295(18):2148-2157.